INMED PHARMACEUTICALS INC. Investing Cash Flow
INMED PHARMACEUTICALS INC. (INM) reported Investing Cash Flow of $0 for the 12-month period ending 2026-06-30, per its S-4/A filed 2026-09-09.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-09-09
- INMED PHARMACEUTICALS INC. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $0.00.
- INMED PHARMACEUTICALS INC. net cash provided by (used in) investing activities for the quarter ending 2025-06-30 was $0.00.
- INMED PHARMACEUTICALS INC. net cash provided by (used in) investing activities for the quarter ending 2024-06-30 was $0.00.
- INMED PHARMACEUTICALS INC. net cash provided by (used in) investing activities for the quarter ending 2024-03-31 was -$2.00.
- INMED PHARMACEUTICALS INC. net cash provided by (used in) investing activities for fiscal 2023 was -$661.80K.
- INMED PHARMACEUTICALS INC. net cash provided by (used in) investing activities for fiscal 2022 was -$673.00K.
- INMED PHARMACEUTICALS INC. net cash provided by (used in) investing activities for fiscal 2021 was -$1.73K, a 100.05% decline from fiscal 2020.
- INMED PHARMACEUTICALS INC. net cash provided by (used in) investing activities for fiscal 2020 was $3.79M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: S-4/A 12 month − S-4 9 month · filed 2026-09-09 | $0.00 S-4/A · filed 2026-09-09 | ||
| 2026-03-31 | $0.00 S-4 · filed 2026-07-02 | |||
| 2025-06-30 | $0.00 derived: S-4/A 12 month − S-4 9 month · filed 2026-09-09 | $0.00 S-4/A · filed 2026-09-09 | ||
| 2025-03-31 | $0.00 S-4 · filed 2026-07-02 | |||
| 2024-06-30 | $0.00 derived: S-4 12 month − 10-Q 9 month · filed 2026-07-02 | -$2.00 derived: sum of 2 quarters · filed 2026-07-02 | -$9.29K S-4 · filed 2026-07-02 | |
| 2024-03-31 | -$2.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-12 | -$9.29K 10-Q · filed 2025-05-12 | ||
| 2023-12-31 | -$9.29K 10-Q · filed 2025-02-12 | |||
| 2023-06-30 | -$33.61K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-30 | -$161.80K derived: sum of 2 quarters · filed 2024-09-30 | -$661.80K 10-K · filed 2024-09-30 | |
| 2023-03-31 | -$128.20K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-15 | -$628.20K 10-Q · filed 2023-05-15 | ||
| 2022-12-31 | -$500.00K 10-Q · filed 2024-02-13 | |||
| 2022-06-30 | -$725.46K derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-29 | -$729.01K derived: sum of 2 quarters · filed 2023-09-29 | -$423.00K derived: sum of 3 quarters · filed 2023-09-29 | -$673.00K 10-K · filed 2023-09-29 |
| 2022-03-31 | -$3.55K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-15 | $302.46K derived: sum of 2 quarters · filed 2023-05-15 | $52.46K 10-Q · filed 2023-05-15 | |
| 2021-12-31 | $306.01K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-02-17 | $56.01K 10-Q · filed 2023-02-17 | ||
| 2021-09-30 | -$250.00K 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | -$1.73K 10-K · filed 2022-09-23 | |||
| 2020-06-30 | $918.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-24 | -$7.88K derived: sum of 2 quarters · filed 2021-09-24 | $47.03K derived: sum of 3 quarters · filed 2021-09-24 | $3.79M 10-K · filed 2021-09-24 |
| 2020-03-31 | -$8.80K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-05-13 | $46.11K derived: sum of 2 quarters · filed 2021-05-13 | $3.79M 10-Q · filed 2021-05-13 | |
| 2019-12-31 | $54.91K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-02-11 | $3.80M 10-Q · filed 2021-02-11 | ||
| 2019-09-30 | $3.74M 10-Q · filed 2020-12-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |